<p>Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target="_blank">Mass General Brigham</a>, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in <a href="https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2814491?utm_campaign=articlePDF&amp;utm_medium=articlePDFlink&amp;utm_source=articlePDF&amp;utm_content=jamainternmed.2023.7660" target="_blank">JAMA Internal Medicine</a>.&nbsp;</p>

Related Keywords

United States , Massachusetts , Garyc Curhan , Julie Paik , Helen Tesfaye , Deborahj Wexler , Heidi Zakoul , Method Of Research , Drug Administration , Outcomes Research Institute , Division Of Renal Kidney Medicine At Brigham , National Institute Of Aging , Glaxosmithkline , Boehringer Ingelheim , Department Of Medicine , Division Of Pharmacoepidemiology , National Institute Of Arthritis , Harvard Medical School , Novo Nordisk , Mass General Brigham , Massachusetts General Hospital , Additional Mass General Brigham , Elisabetta Patorno , National Institute , Patient Centered Outcomes Research Institute , Skin Diseases , Glucose Cotransporter , Nephrolithiasis Risk , Patients With Type , General Brigham ,